Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:ATCCode |
none (as of 2024)
|
| gptkbp:CASNumber |
1802420-43-7
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Amgen
gptkb:Five_Prime_Therapeutics |
| https://www.w3.org/2000/01/rdf-schema#label |
bemarituzumab
|
| gptkbp:macromoleculeType |
humanized monoclonal antibody
|
| gptkbp:mechanismOfAction |
FGFR2b inhibition
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
FPA144
|
| gptkbp:target |
gptkb:FGFR2b
|
| gptkbp:UNII |
1Q1K6P2J1F
|
| gptkbp:usedFor |
gastric cancer
gastroesophageal junction cancer |
| gptkbp:bfsParent |
gptkb:Five_Prime_Therapeutics
|
| gptkbp:bfsLayer |
7
|